Novo Nordisk received FDA approval for a higher 7.2 mg dose of its weight-loss drug Wegovy. The approval, granted under accelerated pathways, was based on positive results from the STEP UP trial. Despite this milestone, Novo Nordisk shares fell nearly 2% in morning trading, with retail sentiment on Stocktwits turning bearish.